Zim Laboratories Ltd
Zim Laboratories is engaged in the manufacturing of formulation drugs and pre formulation ingredients in India and marketing and selling these within and outside India.
- Market Cap ₹ 122 Cr.
- Current Price ₹ 75.0
- High / Low ₹ 131 / 55.0
- Stock P/E 12.1
- Book Value ₹ 95.1
- Dividend Yield 0.00 %
- ROCE 4.75 %
- ROE 1.16 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.79 times its book value
Cons
- Promoter holding is low: 33.26%
- Company has a low return on equity of 7.64% for last 3 years.
- Dividend payout has been low at 3.15% of profits over last 3 years
- Company's cost of borrowing seems high
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
---|---|---|---|---|---|---|
268 | 235 | 272 | 332 | 274 | 298 | |
238 | 203 | 238 | 289 | 255 | 264 | |
Operating Profit | 30 | 32 | 34 | 43 | 20 | 34 |
OPM % | 11% | 14% | 12% | 13% | 7% | 11% |
Other Income | -2 | 5 | 9 | 2 | 5 | -1 |
Interest | 14 | 10 | 9 | 11 | 13 | 11 |
Depreciation | 9 | 9 | 10 | 11 | 13 | 14 |
Profit before tax | 5 | 18 | 24 | 23 | -1 | 8 |
Tax % | 5% | -6% | 24% | 30% | 216% | |
Net Profit | 5 | 19 | 18 | 16 | 2 | 6 |
EPS in Rs | 9.93 | 1.08 | 3.54 | |||
Dividend Payout % | 16% | 4% | 4% | 5% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 5% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -55% |
TTM: | 108% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | 2% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 8% |
Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
---|---|---|---|---|---|---|
8 | 8 | 8 | 16 | 16 | 16 | |
Reserves | 91 | 110 | 128 | 135 | 136 | 138 |
Borrowings | 96 | 81 | 81 | 77 | 90 | 65 |
61 | 60 | 80 | 96 | 81 | 103 | |
Total Liabilities | 256 | 259 | 297 | 325 | 323 | 322 |
92 | 89 | 94 | 101 | 111 | 111 | |
CWIP | 3 | 4 | 8 | 13 | 10 | 5 |
Investments | 0 | 0 | 0 | 5 | 8 | 8 |
161 | 166 | 195 | 206 | 194 | 198 | |
Total Assets | 256 | 259 | 297 | 325 | 323 | 322 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|
22 | 32 | 37 | 37 | 21 | |
-12 | -7 | -26 | -23 | -18 | |
-10 | -25 | -10 | -15 | -3 | |
Net Cash Flow | -0 | -0 | 1 | -1 | 0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
---|---|---|---|---|---|
ROCE % | 14% | 13% | 15% | 5% | |
Debtor Days | 120 | 137 | 119 | 99 | 84 |
Inventory Turnover | 3.42 | 3.37 | 3.13 | 2.70 |
Documents
Recent announcements
- Announcement Under Regulation (30) - Corporate Presentation 9 Apr
- Statement Of Investor Complaints For The Quarter Ended March 2021 8 Apr
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8 Apr
- Closure of Trading Window 27 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 19 Mar
View all